GlassScriptPhysician profile
Esther Wang
NPI 1700523990
$3,258.29
in general payments reported to CMS, 2019-2025
28 companies · $1,376 in 2025
The $1,376 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $606 · 2024: $1,276 · 2025: $1,376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,258.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $418.84 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $333.95 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $278.57 | 2023-2025 | Farxiga, Airsupra, Fasenra |
| Novartis Pharmaceuticals Corporation | $218.42 | 2024-2025 | |
| Glaxosmithkline, LLC. | $218.34 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $205.52 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.27 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $167.87 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $161.58 | 2023-2025 | Rexulti |
| Lundbeck LLC | $117.40 | 2023-2025 | Rexulti, Vyepti |
| Novo Nordisk INC | $106.41 | 2023-2025 | Ozempic, Rybelsus |
| Amgen INC. | $98.31 | 2023-2025 | Evenity, Prolia, Repatha |
| Esperion Therapeutics, INC. | $86.16 | 2024-2025 | Nexletol |
| Sumitomo Pharma America, INC. | $85.79 | 2024-2025 | Gemtesa |
| Edwards Lifesciences Corporation | $82.55 | 2025 | Sapien 3 Ultra Resilia |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $71.23 | 2024-2025 | Verquvo, Capvaxive |
| Janssen Pharmaceuticals, INC | $63.97 | 2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $58.88 | 2025 | Camzyos, Eliquis |
| Scilex Pharmaceuticals INC. | $47.17 | 2024-2025 | |
| Corcept Therapeutics | $47.00 | 2025 | Korlym |
| Actelion Pharmaceuticals US, INC. | $31.74 | 2024 | Opsumit, Uptravi |
| Kiniksa Pharmaceuticals International, Plc | $27.48 | 2024 | Arcalyst |
| Shield Therapeutics INC | $26.26 | 2024 | |
| Eisai INC. | $25.24 | 2024 | |
| Neurocrine Biosciences, INC. | $25.17 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.63 | 2025 | Lifevest |
| Xeris Pharmaceuticals, INC. | $21.56 | 2025 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $17.98 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Esther Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.